Profile data is unavailable for this security.
About the company
Pila Pharma AB is a Sweden-based clinical stage pharmaceutical company, active in the biotechnology sector. The Company conducts clinical tests in phase 2 with drugs against type 2 diabetes. The target product is a tablet that is taken orally in an early stage of diabetes to restore the body's insulin production and thereby reduce the patient's blood sugar level. PILA PHARMA's patent-protected product candidate is called XEN-D0501 and is a TRPV1 antagonist, a novel type of oral anti-diabetic agent for treatment of type 2 diabetes. Pila Pharma AB has completed two phase 2a clinical trials (PP-CT01 and PP-CT02), that both demonstrated that XEN-D0501 is well tolerated by people with type 2 diabetes. In addition, the product is expected to have fewer unwanted side effects than alternative forms of treatment.
- Revenue in SEK (TTM)1.46m
- Net income in SEK-9.93m
- Incorporated2014
- Employees1.00
- LocationPila Pharma ABVastergatan 1MALMO 211 21SwedenSWE
- Websitehttps://pilapharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NextCell Pharma AB | 12.45m | -39.37m | 44.35m | -- | -- | 0.7943 | -- | 3.56 | -1.15 | -1.15 | 0.3621 | 1.62 | 0.1406 | 14.06 | 7.20 | -- | -44.45 | -34.92 | -50.09 | -37.06 | 12.04 | -68.21 | -316.25 | -538.60 | 4.36 | -- | 0.00 | -- | 80.96 | 72.85 | -15.21 | -- | -- | -- |
| Veg of Lund AB (publ) | 4.82m | -19.91m | 44.98m | 7.00 | -- | 1.07 | -- | 9.34 | -0.7328 | -0.7328 | 0.1519 | 1.01 | 0.1337 | 13.74 | 14.40 | 688,000.00 | -55.27 | -129.03 | -82.56 | -209.20 | -384.61 | -781.09 | -413.50 | -923.73 | 0.1256 | -12.90 | 0.1405 | -- | 89.57 | 39.87 | 56.02 | -- | -12.47 | -- |
| Klaria Pharma Holding AB (publ) | 0.00 | -18.39m | 46.86m | 5.00 | -- | 1.14 | -- | -- | -0.1824 | -0.355 | 0.00 | 0.3862 | 0.00 | -- | -- | 0.00 | -19.03 | -37.28 | -31.28 | -51.56 | -- | -- | -- | -2,077.34 | -- | -3.88 | 0.00 | -- | -100.00 | -- | 71.17 | -- | -- | -- |
| Scandion Oncology A/S | 0.00 | -60.98m | 49.51m | 4.00 | -- | 1.02 | -- | -- | -1.51 | -1.51 | 0.00 | 1.19 | 0.00 | -- | -- | 0.00 | -63.25 | -45.09 | -76.67 | -52.65 | -- | -- | -- | -- | -- | -- | 0.0158 | -- | -- | -- | 48.89 | -- | -- | -- |
| SoftOx Solutions AS | 6.97m | -42.04m | 50.49m | -- | -- | -- | -- | 7.24 | -1.98 | -1.98 | 0.3286 | -0.0127 | 0.081 | -- | 1.60 | -- | -48.81 | -50.83 | -82.20 | -64.58 | -- | -- | -602.91 | -646.67 | 0.1745 | -3.45 | -- | -- | -1.88 | 10.06 | 40.85 | -- | 39.43 | -- |
| Alzinova AB | 270.00k | -16.48m | 52.55m | 5.00 | -- | 0.4615 | -- | 194.62 | -0.418 | -0.418 | 0.0067 | 2.56 | 0.0023 | -- | 0.3671 | 54,000.00 | -14.04 | -10.77 | -14.91 | -11.27 | 7,360.92 | -- | -6,103.69 | -18,447.90 | -- | -- | 0.007 | -- | -- | -- | -25.92 | -- | 15.81 | -- |
| Spago Nanomedical AB (publ) | 1.47m | -34.41m | 54.83m | 12.00 | -- | 1.60 | -- | 37.43 | -0.2454 | -0.2454 | 0.0107 | 0.1525 | 0.0324 | -- | 9.90 | 112,692.30 | -76.02 | -20.19 | -90.21 | -20.97 | 115.84 | -- | -2,349.01 | -4,853.45 | -- | -- | 0.00 | -- | 14.14 | -- | -7.72 | -- | -- | -- |
| Orphazyme A/S | 0.00 | -40.52m | 57.63m | 1.00 | -- | 2.60 | -- | -- | -737.75 | -737.75 | 0.00 | 403.34 | 0.00 | -- | -- | 0.00 | -68.42 | -76.08 | -94.18 | -105.34 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 32.00 | -- | -- | -- |
| Pila Pharma AB | 1.46m | -9.93m | 58.06m | 1.00 | -- | 8.72 | -- | 39.68 | -0.5304 | -0.5304 | 0.0767 | 0.28 | 0.1513 | -- | 6.11 | 1,463,020.00 | -102.68 | -108.88 | -122.66 | -121.45 | -127.88 | -42.67 | -678.73 | -1,577.64 | -- | -159.47 | 0.104 | -- | -22.21 | -- | 62.92 | -- | -- | -- |
| PCI Biotech Holding ASA | 2.99m | -20.30m | 60.81m | 7.00 | -- | 1.56 | -- | 20.36 | -0.5443 | -0.5443 | 0.0801 | 1.05 | 0.0556 | -- | 0.6848 | 427,142.80 | -37.78 | -36.44 | -41.97 | -40.14 | -- | -- | -679.43 | -1,055.43 | -- | -- | 0.0081 | -- | -37.05 | -20.78 | 63.13 | -- | -- | -- |
| Combigene AB | 5.54m | -35.67m | 64.95m | 8.00 | -- | 0.5577 | -- | 11.71 | -1.80 | -1.80 | 0.28 | 5.88 | 0.0398 | -- | 2.63 | 693,015.00 | -25.58 | -13.00 | -26.56 | -14.58 | -- | -- | -643.32 | -58.77 | -- | -- | 0.00 | -- | -79.23 | 268.58 | -479.27 | -- | -24.02 | -- |
| Double Bond Phrmcutcl Intrntnl AB (publ) | 1.37m | -17.34m | 65.87m | 10.00 | -- | 11.73 | -- | 48.07 | -0.1837 | -0.1837 | 0.0136 | 0.0556 | 0.1016 | -- | 18.59 | 137,033.00 | -128.49 | -80.90 | -198.98 | -106.45 | -241.22 | -686.41 | -1,265.24 | -1,360.03 | -- | -217.55 | 0.00 | -- | 10.25 | 135.07 | -14.36 | -- | -- | -- |
| Prolight Diagnostics AB (publ) | 0.00 | -135.46m | 65.97m | 16.00 | -- | 0.3442 | -- | -- | -0.4074 | -0.4074 | 0.00 | 0.3835 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -13.84 | -- |
| Immunovia AB (publ) | 1.21m | -260.73m | 67.48m | 11.00 | -- | 1.54 | -- | 55.68 | -6.06 | -6.06 | 0.0276 | 0.9648 | 0.0075 | 58.23 | 14.96 | 110,181.80 | -160.93 | -41.33 | -194.89 | -44.24 | -5,523.76 | -7,553.76 | -21,512.13 | -20,879.29 | 2.03 | -- | 0.1675 | -- | 37.55 | 36.48 | -84.09 | -- | -50.93 | -- |
| ViroGates A/S | 8.92m | -19.83m | 70.00m | 10.00 | -- | 3.35 | -- | 7.85 | -6.00 | -6.00 | 1.44 | 2.08 | 0.3344 | 0.316 | 3.64 | 573,300.00 | -74.36 | -46.58 | -80.05 | -52.09 | 77.20 | 77.91 | -222.40 | -238.01 | 10.45 | -19.08 | 0.2833 | -- | -45.01 | 10.98 | -25.40 | -- | -- | -- |
| ExpreS2ion Biotech Holding AB | 7.77m | -77.95m | 70.12m | 18.00 | -- | 1.34 | -- | 9.03 | -1.56 | -1.56 | 0.1509 | 1.02 | 0.0821 | -- | 4.87 | 298,730.80 | -82.36 | -63.54 | -113.92 | -75.88 | -132.91 | -1.94 | -1,003.55 | -524.31 | -- | -- | 0.0055 | -- | 43.07 | -0.1561 | 22.94 | -- | 19.90 | -- |
Data as of May 21 2024. Currency figures normalised to Pila Pharma AB's reporting currency: Swedish Krona SEK
